Nastoupil Loretta J, Bartlett Nancy L
University of Texas MD Anderson Cancer Center, Houston, TX.
Washington University, Siteman Cancer Center, St Louis, MO.
J Clin Oncol. 2023 Feb 1;41(4):903-913. doi: 10.1200/JCO.22.01848. Epub 2022 Dec 12.
Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases. Several recent advances have affected the treatment landscape, which had been mostly stagnant for the past few decades. We will review the practice-changing studies in frontline (POLARIX), early relapse (ZUMA-7 and TRANSFORM), and multiple recurrent (ZUMA-1, JULIET, TRANSCEND, L-MIND, and LOTIS-2) stages and discuss how the treatment landscape may evolve with the emergence of bispecific antibodies.
弥漫性大B细胞淋巴瘤是非霍奇金淋巴瘤最常见的亚型，由一组形态学、遗传学和临床上不同的异质性疾病组成。最近的一些进展已经影响了治疗格局，而在过去几十年里，治疗格局大多停滞不前。我们将回顾在一线治疗（POLARIX）、早期复发（ZUMA-7和TRANSFORM）以及多次复发（ZUMA-1、JULIET、TRANSCEND、L-MIND和LOTIS-2）阶段改变实践的研究，并讨论随着双特异性抗体的出现，治疗格局可能如何演变。
